Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Tota... (sident and chief executive office...)

HOME >> BIOLOGY >> TECHNOLOGY

Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues

Date:10/30/2007

sident and chief

executive officer of Gilead Sciences, Inc., has been elected to its

board of directors. Gen-Probe's board now has eight members,

including seven who are not Gen-Probe employees.

-- Update on PROCLEIX ULTRIO Post-Marketing Study. To date,

participating blood banks have screened approximately 260,000 blood

donations in the post-marketing study for the PROCLEIX ULTRIO assay,

which is designed to demonstrate hepatitis B virus (HBV) "yield."

Yield is defined as HBV-infected blood donations that were intercepted

by the PROCLEIX ULTRIO assay, but that were initially negative based

on traditional serology tests. Gen-Probe believes that the first of

two required yield cases has been identified in the study, although

this must be confirmed through a regulatory submission to the FDA.

The FDA has approved the PROCLEIX ULTRIO assay to screen donated blood

for HIV-1 and hepatitis C virus (HCV), but not to screen for HBV, as

the initial clinical studies were not designed to, and did not,

demonstrate HBV yield. Gen-Probe and Novartis are conducting the

post-marketing study to demonstrate HBV yield and gain the associated

donor screening claim.

Webcast Conference Call

A live webcast of Gen-Probe's third quarter 2007 conference call for investors can be accessed at http://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours. The replay number is (800) 947-6450 for domestic callers and (203) 369-3539 for international callers.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic aci
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening

Post Your Comments:

Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Tota...(sident and chief executive office...)